REAP Financial Group LLC Raises Stock Position in Gilead Sciences, Inc. $GILD

REAP Financial Group LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 94.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 594 shares of the biopharmaceutical company’s stock after buying an additional 288 shares during the quarter. REAP Financial Group LLC’s holdings in Gilead Sciences were worth $66,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $25,000. Activest Wealth Management lifted its position in shares of Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the last quarter. Goodman Advisory Group LLC purchased a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $29,000. Colonial Trust Advisors raised its position in Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 213 shares during the last quarter. Finally, Core Alternative Capital raised its position in Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 241 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 1.3%

Shares of Gilead Sciences stock opened at $118.25 on Thursday. The company has a market cap of $146.73 billion, a P/E ratio of 23.56, a PEG ratio of 0.79 and a beta of 0.34. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a one year low of $84.17 and a one year high of $121.83. The firm has a fifty day moving average of $114.48 and a two-hundred day moving average of $110.12.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences’s quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were paid a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio is 62.95%.

Insider Activity at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the transaction, the chief executive officer directly owned 605,725 shares of the company’s stock, valued at $69,016,306.50. This represents a 1.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $283,925.00. Following the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at approximately $18,120,661.35. This trade represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 82,000 shares of company stock valued at $9,402,130. Company insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Needham & Company LLC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target for the company in a research report on Friday, July 25th. Dbs Bank upgraded shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Citigroup upped their price target on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $117.67.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.